Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT02189720||Available||Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients||
||Industry||All||2 Years and older (Child, Adult, Older Adult)||NCT02189720||EAP-001||EAP-001||July 15, 2014||October 16, 2018||
|Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)||
||26||All||18 Years and older (Adult, Older Adult)||NCT02970162||LMS-003||November 2016||October 2017||October 2017||November 21, 2016||December 24, 2018||December 24, 2018||